These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 28383660)

  • 1. CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair.
    Shenoy TR; Boysen G; Wang MY; Xu QZ; Guo W; Koh FM; Wang C; Zhang LZ; Wang Y; Gil V; Aziz S; Christova R; Rodrigues DN; Crespo M; Rescigno P; Tunariu N; Riisnaes R; Zafeiriou Z; Flohr P; Yuan W; Knight E; Swain A; Ramalho-Santos M; Xu DY; de Bono J; Wu H
    Ann Oncol; 2017 Jul; 28(7):1495-1507. PubMed ID: 28383660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage.
    Zhu Y; Wen J; Huang G; Mittlesteadt J; Wen X; Lu X
    Prostate; 2021 Jan; 81(1):81-88. PubMed ID: 33022763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness.
    Kari V; Mansour WY; Raul SK; Baumgart SJ; Mund A; Grade M; Sirma H; Simon R; Will H; Dobbelstein M; Dikomey E; Johnsen SA
    EMBO Rep; 2016 Nov; 17(11):1609-1623. PubMed ID: 27596623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of DNA double-strand break repair pathway choice: a new focus on 53BP1.
    Zhang F; Gong Z
    J Zhejiang Univ Sci B; 2021 Jan; 22(1):38-46. PubMed ID: 33448186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumors overexpressing RNF168 show altered DNA repair and responses to genotoxic treatments, genomic instability and resistance to proteotoxic stress.
    Chroma K; Mistrik M; Moudry P; Gursky J; Liptay M; Strauss R; Skrott Z; Vrtel R; Bartkova J; Kramara J; Bartek J
    Oncogene; 2017 Apr; 36(17):2405-2422. PubMed ID: 27841863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A functional ex vivo assay to detect PARP1-EJ repair and radiosensitization by PARP-inhibitor in prostate cancer.
    Köcher S; Beyer B; Lange T; Nordquist L; Volquardsen J; Burdak-Rothkamm S; Schlomm T; Petersen C; Rothkamm K; Mansour WY
    Int J Cancer; 2019 Apr; 144(7):1685-1696. PubMed ID: 30478958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRABID overexpression enables synthetic lethality to PARP inhibitor via prolonging 53BP1 retention at double-strand breaks.
    Ma J; Zhou Y; Pan P; Yu H; Wang Z; Li LL; Wang B; Yan Y; Pan Y; Ye Q; Liu T; Feng X; Xu S; Wang K; Wang X; Jian Y; Ma B; Fan Y; Gao Y; Huang H; Li L
    Nat Commun; 2023 Mar; 14(1):1810. PubMed ID: 37002234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of chromatid-break-repair detects a homologous recombination to non-homologous end-joining switch with increasing load of DNA double-strand breaks.
    Murmann-Konda T; Soni A; Stuschke M; Iliakis G
    Mutat Res Genet Toxicol Environ Mutagen; 2021 Jul; 867():503372. PubMed ID: 34266628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity.
    Becker JR; Cuella-Martin R; Barazas M; Liu R; Oliveira C; Oliver AW; Bilham K; Holt AB; Blackford AN; Heierhorst J; Jonkers J; Rottenberg S; Chapman JR
    Nat Commun; 2018 Dec; 9(1):5406. PubMed ID: 30559443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.
    Dev H; Chiang TW; Lescale C; de Krijger I; Martin AG; Pilger D; Coates J; Sczaniecka-Clift M; Wei W; Ostermaier M; Herzog M; Lam J; Shea A; Demir M; Wu Q; Yang F; Fu B; Lai Z; Balmus G; Belotserkovskaya R; Serra V; O'Connor MJ; Bruna A; Beli P; Pellegrini L; Caldas C; Deriano L; Jacobs JJL; Galanty Y; Jackson SP
    Nat Cell Biol; 2018 Aug; 20(8):954-965. PubMed ID: 30022119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The TMPRSS2-ERG Gene Fusion Blocks XRCC4-Mediated Nonhomologous End-Joining Repair and Radiosensitizes Prostate Cancer Cells to PARP Inhibition.
    Chatterjee P; Choudhary GS; Alswillah T; Xiong X; Heston WD; Magi-Galluzzi C; Zhang J; Klein EA; Almasan A
    Mol Cancer Ther; 2015 Aug; 14(8):1896-906. PubMed ID: 26026052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CTCF facilitates DNA double-strand break repair by enhancing homologous recombination repair.
    Hilmi K; Jangal M; Marques M; Zhao T; Saad A; Zhang C; Luo VM; Syme A; Rejon C; Yu Z; Krum A; Fabian MR; Richard S; Alaoui-Jamali M; Orthwein A; McCaffrey L; Witcher M
    Sci Adv; 2017 May; 3(5):e1601898. PubMed ID: 28560323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastasis Suppressor NME1 Modulates Choice of Double-Strand Break Repair Pathways in Melanoma Cells by Enhancing Alternative NHEJ while Inhibiting NHEJ and HR.
    Puts G; Jarrett S; Leonard M; Matsangos N; Snyder D; Wang Y; Vincent R; Portney B; Abbotts R; McLaughlin L; Zalzman M; Rassool F; Kaetzel D
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32824412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roles for 53BP1 in the repair of radiation-induced DNA double strand breaks.
    Shibata A; Jeggo PA
    DNA Repair (Amst); 2020 Sep; 93():102915. PubMed ID: 33087281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP-mediated repair, homologous recombination, and back-up non-homologous end joining-like repair of single-strand nicks.
    Metzger MJ; Stoddard BL; Monnat RJ
    DNA Repair (Amst); 2013 Jul; 12(7):529-34. PubMed ID: 23684799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dystonia gene THAP1 controls DNA double-strand break repair choice.
    Shinoda K; Zong D; Callen E; Wu W; Dumitrache LC; Belinky F; Chari R; Wong N; Ishikawa M; Stanlie A; Multhaupt-Buell T; Sharma N; Ozelius L; Ehrlich M; McKinnon PJ; Nussenzweig A
    Mol Cell; 2021 Jun; 81(12):2611-2624.e10. PubMed ID: 33857404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PTEN Loss Enhances Error-Prone DSB Processing and Tumor Cell Radiosensitivity by Suppressing RAD51 Expression and Homologous Recombination.
    Pei X; Mladenov E; Soni A; Li F; Stuschke M; Iliakis G
    Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CHAMP1-POGZ counteracts the inhibitory effect of 53BP1 on homologous recombination and affects PARP inhibitor resistance.
    Fujita H; Ikeda M; Ui A; Ouchi Y; Mikami Y; Kanno SI; Yasui A; Tanaka K
    Oncogene; 2022 May; 41(19):2706-2718. PubMed ID: 35393543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homologous Recombination-Mediated DNA Repair and Implications for Clinical Treatment of Repair Defective Cancers.
    Reilly NM; Yard BD; Pittman DL
    Methods Mol Biol; 2019; 1999():3-29. PubMed ID: 31127567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterozygous PALB2 c.1592delT mutation channels DNA double-strand break repair into error-prone pathways in breast cancer patients.
    Obermeier K; Sachsenweger J; Friedl TW; Pospiech H; Winqvist R; Wiesmüller L
    Oncogene; 2016 Jul; 35(29):3796-806. PubMed ID: 26640152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.